In this issue:
- Pembrolizumab for advanced clear-cell gynaecological cancers
- Promising new blood test to detect early pancreatic cancer
- Daratumumab delays progression from smouldering to active multiple myeloma
- Cabozantinib for advanced neuroendocrine tumours
- No benefit for PD-L1 inhibitor compared with cetuximab in platinum-ineligible patients undergoing radiotherapy for HNSCC
- Māori travel longer distances to access bronchoscopy for lung cancer
- Updated melanoma guidelines from ESMO
- Pilot study supports professional supervision to enhance job satisfaction in radiation oncology
- Pharmac funds new treatments for liver, ovarian, neuroendocrine, lung and kidney cancers
- Pharmac funds denosumab for malignant hypercalcaemia in patients with renal damage
- Change to the funded palbociclib brand
- Sonobiopsy is looking feasible for noninvasive diagnosis of brain tumours
- Antibody-drug conjugates for breast cancer: new FDA approvals and indications
- Escherichia coli as an anticancer tool?
- Gender-affirming hormone therapy and the risk of prostate cancer in transgender women
Please login below to download this issue (PDF)